Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ESGO statement on cervical cancer vaccination.
Vergote I, van der Zee AG, Kesic V, Sert B, Robova H, Rob L, Reed N, Luesley DM, Leblanc E, Hagen B, Gitsch G, du Bois A, di Vagno G, Colombo N, Beller U, Ayhan A, Jacobs I. Vergote I, et al. Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1183-5. doi: 10.1111/j.1525-1438.2007.01129.x. Int J Gynecol Cancer. 2007. PMID: 17997794 No abstract available.
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Vergote I, et al. Among authors: reed ns. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806. N Engl J Med. 2010. PMID: 20818904 Free article. Clinical Trial.
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial.
Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I. Verleye L, et al. Among authors: reed ns. Eur J Cancer. 2011 Jan;47(1):57-64. doi: 10.1016/j.ejca.2010.08.008. Epub 2010 Sep 16. Eur J Cancer. 2011. PMID: 20850296 Clinical Trial.
Training in bowel and upper abdominal surgery in gynaecological oncology: European Society of Gynecological Oncology (ESGO) Statement.
Cibula D, Verheijen R, Lopes A, Amant F, Beller U, Colombo N, Gitsch G, Kesic V, Kimmig R, Markowska J, Marth C, Reed N, Rodolakis A, Salvesen H, Vaitkiene D, van der Zee AG, Zola P. Cibula D, et al. Int J Gynecol Cancer. 2011 Oct;21(7):1264-5. doi: 10.1097/IGC.0b013e3182208141. Int J Gynecol Cancer. 2011. PMID: 21720255 No abstract available.
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I; European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group. Greimel E, et al. Among authors: reed ns. Gynecol Oncol. 2013 Nov;131(2):437-44. doi: 10.1016/j.ygyno.2013.08.014. Epub 2013 Aug 27. Gynecol Oncol. 2013. PMID: 23994107 Clinical Trial.
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, Armenio VA, Duska L, Poole C, Gennigens C, Dirix LY, Leung AC, Zhao C, Soufi-Mahjoubi R, Rustin G. Vergote IB, et al. J Clin Oncol. 2013 Nov 10;31(32):4060-6. doi: 10.1200/JCO.2012.45.1278. Epub 2013 Sep 30. J Clin Oncol. 2013. PMID: 24081946 Free PMC article. Clinical Trial.
247 results